Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Oral Squamous Cell Carcinoma (OSCC)
Interventions: Olaparib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Colon Cancer, Rectal Cancer
Interventions: Patient Navigator; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 25 Years to 75 Years
Enrollment: 1,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Osteoarthritis
Interventions: Not applicable (no therapy is administered as part of this study); Other
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 62
States / cities: Birmingham, Alabama • Oro Valley, Arizona • Phoenix, Arizona + 59 more

Conditions: Healthy Participants
Interventions: Aficamten, Aficamten-matching Placebo, Moxifloxacin; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
Interventions: Tazemetostat, Itraconazole, Rifampin; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more

Conditions: Hypertension, Renal
Interventions: MLS-101 (Part I), Placebo (Part I), Placebo (Part II), MLS-101 (Part II); Drug · Other
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 44
States / cities: Lincoln, California • Torrance, California • Tustin, California + 38 more

Conditions: Healthy, Rheumatoid Arthritis
Interventions: IA-14069, Placebo, Methotrexate; Drug
Lead sponsor: ILAb Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Neoplasms
Interventions: Refametinib (BAY86-9766), Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: New Haven, Connecticut • Detroit, Michigan • St Louis, Missouri + 2 more

Conditions: Macular Degeneration
Interventions: VEGF Trap; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more

Conditions: Phenylketonurias
Interventions: Skin Tape, Blood Draw; Other · Diagnostic Test
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hematologic Malignancies
Interventions: CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus; Device · Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Nivolumab, Ipilimumab (3 mg/kg); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cystic Fibrosis
Interventions: lumacaftor, ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Volunteers
Interventions: Maribavir; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Respiratory Distress Syndrome, Hyperoxia, Prematurity
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 3 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Non-small Cell Lung Cancer
Interventions: gemcitabine, docetaxel, cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 10
States / cities: Denver, Colorado • South Bend, Indiana • Baltimore, Maryland + 7 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: MSGV1-PSCA-8T28Z, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Burnout, Professional
Interventions: hybrid asynchronous-synchronous group coaching program, treatment as usual group (TAU); Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Atlanta, Georgia

Conditions: Concussion, Brain
Interventions: [11C] PiB, [18F] PBR111, [18F] Flortaucipir; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 70 Years · Male only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 3
States / cities: Waltham, Massachusetts • Chapel Hill, North Carolina • Milwaukee, Wisconsin

Conditions: Irritable Bowel Syndrome
Interventions: Placebo, Camlipixant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 112
States / cities: Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 91 more

Conditions: Chronic Kidney Disease (CKD), Hyperkalemia (HK)
Interventions: Patiromer, Placebo; Drug
Lead sponsor: Relypsa, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 14
States / cities: Azusa, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Metastatic Neoplasm
Interventions: MK-8294, CD8 PET Tracer; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Chicago, Illinois • Hackensack, New Jersey • Houston, Texas

Conditions: Cancer
Interventions: Oncologist Recommendation, Oncologist Recommendation + DVD; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Problem Drinking, Aggression, Stress, Psychological
Interventions: Mindfulness-Based Resilience Training (MBRT); Behavioral
Lead sponsor: Pacific University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Forest Grove, Oregon

Search by objective public record fields.

A Dye for the Detection of Cancer of the Tongue and Mouth

Adherence to Colon Cancer Screening (ACCS)

An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

MAD Study of IA-14069

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

PKU Skin Stripping

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Coaching for Advanced Practice Providers

NFL LONG Prospective Study

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

Exercise Information for Women With Cancer

Feasibility and Acceptability of Mindfulness-based Resilience Training for Rural Law Enforcement Officers